Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...

As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

As grim as the likely loss of the U.K. market for the drug may be, Lilly is far from helpless, and the damage, while notable, might not actually drag on its growth by a noticeable amount if its ...

According to its recent 13F filing, the Duquesne Family Office headed by billionaire portfolio manager Stanley Druckenmiller ...

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...